A Phase 4 interventional study of FP and SFC in Asthma, sponsored by GlaxoSmithKline. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2016-12-16.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 117th largest by enrollment of the 146 interventional ones that give a count, is one of 18 that started in 2007, is one of 52 in phase 4, and was the 42nd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 18 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 197th largest by enrollment of the 238 interventional ones that give a count, is one of 20 that started in 2007, is one of 53 in phase 4, and was the 57th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
The aim of the present study is to investigate whether the effects of salmeterol in combination with fluticasone propionate on blood markers of airway inflammation are maintained after chronic dosing and whether the effect is influenced by the time of allergen challenge relative to the time of dosing.
A 12-week, randomised, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate, fluticasone propionate and placebo on perpheral blood eosinophils and serum IL-5 in response to allergen challenge in asthma subjects when allergen challenge is administered at 1 hour or 11-12 hours post-dose of the dosing interval
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period
Drug: FP · Drug: SFC · Drug: Placebo
Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
Drug: FP · Drug: SFC · Drug: Placebo
Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period
Drug: FP · Drug: SFC · Drug: Placebo
Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
Drug: FP · Drug: SFC · Drug: Placebo
Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
Drug: FP · Drug: SFC · Drug: Placebo
Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
Drug: FP · Drug: SFC · Drug: Placebo
Fluticasone Propionate 100 mcg BD
Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
Matching Placebo
Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 35
Number of peripheral blood eosinophils measured from blood draws
Time frame: 0-6 hours post allergen challenge, 10-11 hours post treatment, Day 35
Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 14
Number of peripheral blood eosinophils measured from blood draws
Time frame: 0-6 hours, post allergen challenge, 1 hour post treatment, Day 14
Weighted Mean Change From Baseline Over 0-6 Hours in Serum IL-5 Post-Allergen Challenge on Day 35
Amount of serum interleukin (IL)-5 measured from blood draws
Time frame: 0-6 hours post allergen challenge, 10-11 hours post treatment, Day 35
Weighted Mean Change From Baseline Over 0-6 Hours in Serum IL-5 Post-Allergen Challenge on Day 14
Amount of serum IL-5 measured from blood draws
Time frame: 0-6 hours post allergen challenge, 1 hour after dosing, Day 14
| Milestone | Sequence 1: FP, SFC, Placebo | Sequence 2: Placebo, SFC, FP | Sequence 3: SFC, FP, Placebo | Sequence 4: SFC, Placebo, FP | Sequence 5: FP, Placebo, SFC | Sequence 6: Placebo, FP, SFC |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 3 | 4 | 4 |
| Completed | 4 | 4 | 4 | 3 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: FP, SFC, Placebo | Sequence 2: Placebo, SFC, FP | Sequence 3: SFC, FP, Placebo | Sequence 4: SFC, Placebo, FP | Sequence 5: FP, Placebo, SFC | Sequence 6: Placebo, FP, SFC |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 3 | 4 | 4 |
| Completed | 4 | 4 | 4 | 3 | 3 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Sequence 1: FP, SFC, Placebo | Sequence 2: Placebo, SFC, FP | Sequence 3: SFC, FP, Placebo | Sequence 4: SFC, Placebo, FP | Sequence 5: FP, Placebo, SFC | Sequence 6: Placebo, FP, SFC |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 3 | 3 | 4 |
| Completed | 4 | 4 | 4 | 3 | 3 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Number of peripheral blood eosinophils measured from blood draws
| Giga Units per Liter (GI/L) | Placebo | FP 100 mcg BID | SFC 50/100 mcg BID |
|---|---|---|---|
| Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 35 | -0.050 (-0.072 to -0.029) | -0.040 (-0.061 to -0.019) | -0.023 (-0.044 to -0.001) |
Number of peripheral blood eosinophils measured from blood draws
| Giga Units per Liter (GI/L) | Placebo | FP 100 mcg BID | SFC 50/100 mcg BID |
|---|---|---|---|
| Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 14 | -0.023 (-0.039 to -0.006) | -0.022 (-0.038 to -0.007) | -0.013 (-0.029 to -0.004) |
Amount of serum interleukin (IL)-5 measured from blood draws
Results for this outcome have not been posted.
Amount of serum IL-5 measured from blood draws
Results for this outcome have not been posted.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/22 (0%) | 14/22 (63.6%) |
| FP 100 mcg BID | — | 0/23 (0%) | 16/23 (69.6%) |
| SFC 50/100 BID | — | 1/22 (4.5%) | 10/22 (45.5%) |
| Event | Placebo | FP 100 mcg BID | SFC 50/100 BID |
|---|---|---|---|
| AppendicitisInfections and infestations | 0/22 | 0/23 | 1/22 |
| Event | Placebo | FP 100 mcg BID | SFC 50/100 BID |
|---|---|---|---|
| HeadacheNervous system disorders | 7/22 | 3/23 | 2/22 |
| NasopharyngitisInfections and infestations | 2/22 | 3/23 | 2/22 |
| Pharyngolarngeal PainRespiratory, thoracic and mediastinal disorders | 1/22 | 2/23 | 2/22 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 1/22 | 2/23 | 0/22 |
| DiarrheaGastrointestinal disorders | 1/22 | 1/23 | 0/22 |
| Dry ThroatRespiratory, thoracic and mediastinal disorders | 0/22 | 1/23 | 1/22 |
| HypersensitivityImmune system disorders | 0/22 | 1/23 | 1/22 |
| NauseaGastrointestinal disorders | 1/22 | 1/23 | 0/22 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 0/22 | 1/23 | 1/22 |
| RhinorrheaRespiratory, thoracic and mediastinal disorders | 1/22 | 0/23 | 1/22 |
| Age, Continuous(years) | Overall Study Population |
|---|---|
| Mean | 36.6 ± 6.63 |
| Gender(Participants) | Overall Study Population |
|---|---|
| Female | 9 |
| Male | 14 |
| Race/Ethnicity, Customized(participants) | Overall Study Population |
|---|---|
| African American | 2 |
| Caucasian | 21 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Aug 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone